---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-074439"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:00:17.269171+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion reports 30% MACE-4 risk reduction with bempedoic acid in primary prevention CLEAR Outcomes subanalysis

## Summary
- Primary prevention population (4,206 statin-intolerant patients) showed 30% risk reduction in MACE-4 (HR 0.70) vs placebo.
- 36% MACE-3 risk reduction (HR 0.64) and 39% reduction in CV mortality (HR 0.61).
- All-cause mortality reduced by 27% (HR 0.73). LDL-C lowered 21.3% after 6 months; hsCRP lowered 21.5% after 12 months.
- Data presented at ADA 2023 and simultaneously published in JAMA on June 24, 2023.
- Nearly two-thirds (66.1%) of primary prevention patients had diabetes; safety consistent with prior trials.

## SEC filing metadata
- accession: 0001104659-23-074439
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/0001104659-23-074439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/tm2319637d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-074439
- JSON: https://secwatch.observer/filing/0001104659-23-074439.json
- Plain text: https://secwatch.observer/filing/0001104659-23-074439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.